Generic Name and Formulations:
Naltrexone HCl 50mg; scored tabs.
Indications for REVIA:
Adjunct in treatment of alcohol or narcotic dependence.
Confirm 7–10 day opioid-free period, if questionable do Narcan challenge test (see literature). ≥18yrs: Alcoholism: 50mg daily. Narcotic dependence: Initially 25mg, if no withdrawal symptoms increase to 50mg daily; alternative dosing schedules: see literature.
<18yrs: not recommended.
Concomitant opioids, current opioid dependence, or acute opioid withdrawal. Failed Narcan challenge test or (+) urine screen for opioids. Acute hepatitis. Liver failure.
Liver disease. Monitor liver function. Warn patients of danger of attempting to overcome opiate blockade. Severe renal dysfunction. Possible acute abstinence syndrome. Depression. Suicidal ideation. Pregnancy (Cat.C). Nursing mothers.
Thioridazine increases sedation. Antagonizes opioids (eg, antitussives, antidiarrheals, analgesics). Disulfiram.
Hepatotoxicity, withdrawal reactions; others, see literature.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Age of Onset of Bipolar Disorder Linked With Substance Use Disorders
- Low Testosterone Linked With Social Anxiety in Boys With Klinefelter Syndrome
- Posttraumatic Stress Disorder Associated With Reduced Brain Volume
- First-Episode Drug-Naive Patients With Schizophrenia More Likely to Attempt Suicide
- ADHD Medications Compared for Efficacy, Tolerability in Children and Adults
- The Psychology of Hoarding Disorder: Approaches for Treatment
- Mind-Body Therapy and Psychiatry: Ancient Tools for Modern Practice
- Smartphone Applications for Depression and Anxiety: Are They Ready for Widespread Use?
- The Many Misconceptions of Catatonia: Treatment Is Often Successful With the Right Knowledge
- Marijuana Use Associated With Poorer Depression Outcomes, Increased Suicidal Ideation